Publication | Open Access
Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer
20
Citations
5
References
2016
Year
Grade 1 Topical metronidazole, oral doxycycline (100 mg/day) Complete resolution c No a Following National Cancer Institute CTCae V4.02. b erythemato-telangiectatic rosacea. c 4 and 8 weeks after the last dose of nivolumab, respectively.
| Year | Citations | |
|---|---|---|
Page 1
Page 1